As per MRFR analysis, the US Gallstone Market Size was estimated at 69.3 (USD Million) in 2023. The US Gallstone Market Industry is expected to grow from 75.6 (USD Million) in 2024 to 187 (USD Million) by 2035. The US Gallstone Market CAGR (growth rate) is expected to be around 8.582% during the forecast period (2025 - 2035).
The US Gallstone Market is witnessing significant trends primarily driven by the rising prevalence of gallstone disease, which is linked to factors such as obesity, diabetes, and sedentary lifestyles common in the population. As awareness of gallstone-related health issues increases, the demand for diagnostic and treatment options, including surgery and non-invasive interventions, is also rising. Advancements in medical technology and minimally invasive surgical techniques have improved patient outcomes and fueled market growth.
Opportunities in the market include the expansion of telemedicine services for consultations, which has gained traction, especially post-pandemic. This trend allows patients access to specialists without travel burdens, making diagnosis and management more accessible. Additionally, the integration of artificial intelligence in diagnostic tools promises more accurate detection of gallstones, which could enhance treatment protocols and patient care.
Recent trends also show a growing focus on lifestyle and dietary modifications to prevent gallstone formation. Public health initiatives aimed at educating the population on healthy eating practices can create an avenue to promote products and services that address gallstone prevention. Moreover, the increase in health awareness campaigns by organizations like the American College of Gastroenterology serves to propel preventive measures. As the US population continues to age, the market is expected to evolve, possibly skewing towards treatments catering to older adults who are more susceptible to gallstone issues. Such dynamics within the US Gallstone Market highlight both challenges and avenues for growth and innovation in healthcare solutions.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The alarming rise in obesity rates within the United States is one of the significant drivers for growth in the US Gallstone Market Industry. According to the Centers for Disease Control and Prevention (CDC), more than 42% of adults in the US were categorized as obese during the year 2020, which marks a steep increase from previous years. It has been well-established that obesity significantly contributes to gallstone formation due to increased cholesterol levels in bile.
The National Institute of Diabetes and Digestive and Kidney Diseases further underscores this connection, noting that individuals with a body mass index (BMI) of 30 or higher are at a greater risk of developing gallstones. The rising trend of obesity and its associated health complications signify a potential increase in demand for gallstone treatment options and interventions, positively influencing the US Gallstone Market Industry dynamics.
The US Gallstone Market Industry is significantly driven by advancements in medical technologies, particularly in the fields of diagnostic imaging and minimally invasive surgical techniques. Recent developments in endoscopic procedures, such as endoscopic retrograde cholangiopancreatography (ERCP), have enhanced the effectiveness of gallstone diagnosis and treatment. The American College of Gastroenterology reports that ERCP has improved success rates in treating common bile duct stones.
Furthermore, the introduction of laparoscopic cholecystectomy has revolutionized gallbladder surgeries, allowing for quicker recovery times and reduced hospital stays. These technological advancements are crucial as they attract more patients seeking effective treatment, thereby contributing to the growth of the US Gallstone Market Industry.
The demographic shift towards an aging population in the United States is another critical driver of the US Gallstone Market Industry. According to the Administration for Community Living, by the year 2030, all baby boomers will be over the age of 65, resulting in about 78 million individuals in this age group. Older adults are at a higher risk for gallstones, as gallstone prevalence increases with age due to factors like hormonal changes and cholesterol metabolism alterations.
As the aging population expands, it is expected that the number of patients requiring gallstone diagnosis and treatment services will rise, thereby propelling the demand in the US Gallstone Market Industry.
The US Gallstone Market is characterized by various causes contributing to its prevalence, which significantly shapes the market dynamics. The primary causes include cholesterol stones, bilirubin, concentrated bile, and others, all of which are important to understand for effective diagnosis and treatment strategies.
Cholesterol stones, representing a considerable portion of gallstone cases, arise due to an imbalance in the substances that make up bile. This particular type of gallstone is significant because it is often related to lifestyle factors such as diet and obesity, conditions that are increasingly prevalent in the United States. The growing incidence of obesity among adults and children, with roughly 40% of the adult population classified as obese, creates a substantial opportunity for market expansion in terms of both prevention and treatment options.
Bilirubin stones, on the other hand, are associated with certain medical conditions, such as liver or blood disorders, which increase bilirubin in bile. This segment plays a critical role as it indicates underlying health issues that require comprehensive management and can lead to more complex interventions. Attention to the causes of bilirubin stone formation could present opportunities for advancements in treatments and therapies aimed at managing these specific health concerns. Concentrated bile also contributes to gallstone formation and is often a result of conditions that affect gallbladder function. Understanding this cause helps healthcare providers focus on treatment protocols that address gallbladder health, thereby improving overall patient outcomes.
The 'Others' category encompasses various less common causes contributing to gallstone formation, which highlights the diversity of gallstone formations and the need for tailored healthcare solutions. The classification into these different causes allows for better targeting of research and development in treatment options, as well as understanding the epidemiology surrounding gallstones. With an aging population in the US, the market for treatment and management continues to undergo transformations influenced by these underlying causes. The prevalence of gallstones holds significant healthcare implications, especially given the economic burden associated with treatment procedures such as cholecystectomy. As the US Gallstone Market continues to evolve, each of these causes plays a fundamental role in shaping the industry, highlighting the need for thorough research and targeted healthcare approaches to mitigate risks associated with gallstone formation.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Diagnosis segment of the US Gallstone Market plays a crucial role in identifying gallstones' presence and severity, which directly impacts treatment decisions. Ultrasound remains a highly preferred method due to its non-invasive nature and ability to quickly assess gallbladder conditions. Abdominal CT scans offer detailed imaging, allowing for precise diagnostic capabilities, especially in complex cases where additional conditions may be present.
Gallbladder radionuclide scans, while less common, are valuable in evaluating gallbladder function, particularly when traditional imaging methods do not yield conclusive results. Blood tests, despite their limitations in direct gallstone detection, are often used to rule out infection and assess liver function, highlighting their supportive role in the diagnostic pathway. Overall, the emphasis on accurate and timely diagnosis in the US Gallstone Market drives advancements in technology and methodology within these diagnostic tools, reflecting the industry's commitment to improving patient outcomes. Additionally, the rising prevalence of lifestyle-related conditions linked to gallstones in the US further fuels the need for effective diagnostic solutions, ensuring that healthcare providers are well-equipped to address these challenges.
The Treatment segment of the US Gallstone Market is pivotal in addressing the prevalence of gallstones, which affects a significant portion of the population. This segment includes various approaches such as Open cholecystectomy and Laparoscopic cholecystectomy. Open cholecystectomy, traditionally viewed as the standard surgical method, has decreased in popularity due to advancements in Laparoscopic cholecystectomy, which offers reduced recovery times and less invasive procedures. Laparoscopic techniques are preferred for their benefits, contributing to the efficiency of gallstone management in outpatient settings.
Additionally, Medication plays a crucial role, particularly for patients who are unsuitable candidates for surgical options, providing an alternative for gallstone dissolution. Moreover, the category labeled as “Others” encompasses innovative therapies and non-surgical treatments for gallstones, reflecting evolving treatment paradigms driven by technological advancements. Trends within the US Gallstone Market indicate a growing emphasis on minimally invasive treatments to enhance patient recovery experiences. The increasing awareness regarding the risks associated with untreated gallstones further fuels the demand for effective treatment options, creating opportunities for market growth and diversification. With a focus on improving patient outcomes, healthcare providers are continuously exploring novel approaches, further enriching the US Gallstone Market landscape.
The US Gallstone Market is characterized by a dynamic landscape where various companies compete to address the increasing prevalence of gallstones and associated disorders. As awareness about the health risks linked to gallstones grows, the new treatment solutions and technologies continue to emerge, enhancing competition in the market. Companies are investing significantly in research and development to innovate and improve treatment options, including minimally invasive surgical procedures and advanced diagnostic tools. This market has also witnessed a surge in demand for pharmacological interventions, which represent an important segment of the overall healthcare offerings. The competitive insights highlight not only the different strategies employed by market players but also the evolving regulatory environment and patient-centric approaches driving growth in this sector.
Hologic has established itself as a significant player in the US Gallstone Market through a focused approach on women's health and precision diagnostics. The company leverages its expertise in advanced imaging technologies and minimally invasive surgical procedures to enhance patient outcomes. Hologic's strength lies in its commitment to innovation and dedication to research, allowing for the introduction of new products that cater specifically to gallstone disease management. Furthermore, its well-established distribution network and partnerships with healthcare providers across the US enable Hologic to maintain a robust market presence. This deep engagement in the gallstone arena highlights Hologic's ability to navigate the complexities of regulatory approvals and clinical validations that impact market dynamics. The company’s investments in clinical trials and collaboration with research institutions further positions it as a trusted authority in gallstone treatment, reinforcing its competitive advantage.
Merck and Co. is another prominent entity within the US Gallstone Market, known for its comprehensive portfolio of pharmaceutical products aimed at treating gallstone-related conditions. The company offers a range of therapies, including those that focus on pain management and treatment of gallstone complications. Merck's reputation is bolstered by its robust research and development capabilities, which drive innovation in treatment solutions. Notably, the company has a strategy of strategic mergers and acquisitions that have enhanced its market position and expanded its product offerings. This approach allows Merck to remain agile in responding to market demands and improving patient care by integrating cutting-edge technologies and expertise acquired through partnerships. With a strong commitment to clinical excellence and a solid footprint in the US healthcare ecosystem, Merck and Co. continues to strengthen its influence in the gallstone market, focusing on producing effective therapies that address unmet medical needs.
The US Gallstone Market has witnessed notable developments recently, particularly related to new therapeutic options and advancements in minimally invasive surgical techniques. Companies like Medtronic and Boston Scientific are innovating in the space, enhancing treatment efficacy and patient outcomes.
In terms of mergers and acquisitions, Hologic announced the acquisition of a minimally invasive technology company in September 2023, aimed at strengthening its portfolio in diagnostic and therapeutic solutions for gallstone disease. There has also been significant growth in the market valuation for Abbott Laboratories and Pfizer, driven by increased demand for advanced diagnostics and treatment solutions over the last two years, due in part to a rise in gallstone incidence among the population, particularly in adults over 40, as documented by the Centers for Disease Control and Prevention (CDC).
Moreover, the FDA has recently streamlined approval processes for gallstone treatment devices, further propelling the market. As per reports from industry associations, the US Gallstone Market is projected to expand notably in the coming years, reflecting ongoing innovations and strategic alliances among leading healthcare companies.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 69.3(USD Million) |
| MARKET SIZE 2024 | 75.6(USD Million) |
| MARKET SIZE 2035 | 187.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.582% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Hologic, Merck and Co., C. R. Bard, BristolMyers Squibb, Medtronic, Boston Scientific, Abbott Laboratories, Thermo Fisher Scientific, Pfizer, Stryker, Amgen, AbbVie, Cook Medical, Johnson and Johnson, Intuitive Surgical |
| SEGMENTS COVERED | Cause, Diagnosis, Treatment |
| KEY MARKET OPPORTUNITIES | Rising prevalence of gallstones, Advancements in minimally invasive treatments, Growth in telemedicine consultations, Increased awareness and education initiatives, Development of targeted dietary supplements |
| KEY MARKET DYNAMICS | rising obesity rates, increasing aging population, advancements in treatment options, growing awareness and diagnosis, high healthcare costs |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Gallstone Market is expected to be valued at 75.6 million USD in 2024.
The US Gallstone Market is expected to grow at a CAGR of 8.582 percent from 2025 to 2035.
By 2035, the US Gallstone Market is anticipated to reach a value of 187.0 million USD.
In 2024, the Cholesterol stone segment leads the US Gallstone Market with a valuation of 30.0 million USD.
The Bilirubin segment is valued at 20.0 million USD in 2024 and is projected to reach 50.0 million USD by 2035.
Key players in the US Gallstone Market include Hologic, Merck and Co., and C. R. Bard among others.
The Concentrated bile segment is expected to be valued at 36.0 million USD in 2035.
The market may face challenges such as regulatory hurdles and rising competition during its growth phase.
Emerging trends include technological advancements in treatment options and increasing awareness about gallstone diseases.
The 'Others' segment is valued at 10.6 million USD in 2024 within the US Gallstone Market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
